Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
NOVAKA PHARMA from Nivelles, company number BE0723816176, closed financial year 2025 with a result of € 31,857 after tax. For that financial year NOVAKA PHARMA recorded a gross margin of € 117,021 and equity of € 78,789. Compared with financial year 2024, the result moved from € 82,165 to € 31,857. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 3, 2026.
€ 78,789
▲ 68% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 31,857
▼ 61% vs 2024
Profit after tax over the fiscal year.
€ 30,076
▲ 150% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 60,189.
People and assets in 2025
€ 32,094
▲ 4% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 811,028
▼ 11% vs 2024
€ 120,766 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 518
▼ 86% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 27,681
▲ 7% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 183,294 | € -28,335 | € 156,428 | € 117,021 | ▼ 25% |
| Profit after taxes | € 117,900 | € -90,793 | € 82,165 | € 31,857 | ▼ 61% |
| Equity | € 49,360 | € -35,233 | € 46,932 | € 78,789 | ▲ 68% |
| Total debts | € 1,125,399 | € 1,160,412 | € 1,074,010 | € 1,021,597 | ▼ 5% |
| Cash | € 58,828 | € 18,757 | € 12,035 | € 30,076 | ▲ 150% |
| Land & buildings | € 272,616 | € 263,436 | € 258,066 | € 248,769 | ▼ 4% |
| Retained profit | € 36,960 | € -53,833 | € 28,332 | € 60,189 | ▲ 112% |
| Dividend | € 100,000 | € 0 | € 0 | € 0 | |
| Bank debt | € 788,773 | € 1,010,991 | € 908,476 | € 811,028 | ▼ 11% |
| Balance sheet total | € 1,174,759 | € 1,125,179 | € 1,120,942 | € 1,100,386 | ▼ 2% |
By gross margin, NOVAKA PHARMA ranks 8th of 10 companies with main activity “Detailhandel in farmaceutische producten” in Nivelles that publish figures (fiscal year 2025).
Key figures of NOVAKA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about NOVAKA PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to NOVAKA PHARMA?
What happened at NOVAKA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 31,857 (▼ 61% vs 2024). filed late Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Anderlecht. KBO
- New establishment in Nivelles. KBO
In short
From € 117,900 profit in 2022 to € 31,857 profit in 2025.
Paid € 25,124 in corporate taxes since 2022.
Best year ever: 2022, with € 117,900 profit.
Paid out € 100,000 in dividends to the owners in total.
Management
Behind NOVAKA PHARMA is Minh-Tuan LE. It owns 100% of DE RUYCK-ROSSEELS itself.
Directors
According to the 2025 annual accounts
Minh-Tuan LE
Director
Establishments
Establishment units
Physical locations of this company
Rue de Soignies 11
1400 Nivelles
Itterbeekse Laan 184
1070 Anderlecht
Active since 29 March 2019
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Nivelles
Same main activity (Detailhandel in farmaceutische producten), 11 active companies in Nivelles, largest first.
€ 24 million revenue · 2025
€ 831,424 gross margin · 2025
€ 415,999 gross margin · 2025
€ 406,486 gross margin · 2025
€ 332,643 gross margin · 2025
€ 278,623 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- LE Minh Tuan(oprichter, associé unique) 100%
Details
- Company number
- 0723.816.176
- VAT number
- BE 0723.816.176
- Registered office
- Rue de Soignies 11, 1400 Nivelles
- Names & denominations
- NOVAKA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 March 2019
- Peppol
- Active · Active since 9 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten